Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients

American Journal of Transplantation

Volumn 7, Issue 1, 2007, Pages 235-242

  Yazaki, M ^a   Mitsuhashi, S ^a   Tokuda, T ^a   Kametani, F ^b   Takei, Y I ^a   Koyama, J ^a   Kawamorita, A ^c   Kanno, H ^d   Ikeda, S I ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c Ofunato Hospital   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Familial amyloid polyneuropathy; Liver transplantation; Wild type transthyretin

Indexed keywords

AMYLOID; LEUCINE; PREALBUMIN; VALINE;

ADULT; ARTICLE; AUTOPSY; CASE REPORT; DISEASE COURSE; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; HEART DISEASE; HEART MUSCLE; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; ION TRAP MASS SPECTROMETRY; KIDNEY; LIQUID CHROMATOGRAPHY; LIVER TRANSPLANTATION; MASS SPECTROMETRY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN VARIANT; SCIATIC NERVE;

AMYLOID NEUROPATHIES, FAMILIAL; FEMALE; HUMANS; LIVER TRANSPLANTATION; MIDDLE AGED; MYOCARDIUM; PREALBUMIN;

EID: 33845608550     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01585.x     Document Type: Article

References (23)

1. Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin type amyloid polyneuropathy in Japan: Clinical and genetic heterogeneity. Neurology 2002; 58: 1001-1007.
2. Stangou AJ, Hawkins PN. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol 2004; 17: 615-620.
3. Ando Y, Tanaka Y, Nakazato M et al. Change in variant transthyretin levels in patients with familial amyloidostic polyneuropathy type I following liver transplantation. Biochem Biophys Res Commun 1995; 211: 354-358.
4. Holmgren G, Ericzon BG, Groth CG et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113-1116.
5. Bergethon PR, Sabin TD, Lewis D, Simms RW, Cohen AS, Skinner M. Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation. Neurology 1996; 47: 944-951.
6. Takei Y, Ikeda S, Hashikura Y, Ikegami T, Kawasaki S. Partial liver transplantation from living donors in familial amyloid polyneuropathy: A follow-up study of the first 11 patients. Ann Intern Med 1999; 131: 592-595.
7. Adams D, Samuel D, Goulon-Goeau C et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000; 123: 1495-1504.
8. de Carvalho M, Conceição I, Bentes C, Luís MLS. Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid 2002; 9: 126-133.
9. Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997; 64: 74-80.
10. Stangou AJ, Hawkins PN, Heaton ND et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy. Transplantation 1998; 66: 229-233.
11. Olofsson BO, Backman C, Karp K, Suhr OB. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002; 73: 745-751.
12. Westermark P, Sletten K, Johansson B, Cornwell GG. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 1990; 7: 2843-2845.
13. Yazaki M, Tokuda T, Nakamura A et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 2000; 274: 702-706.
14. Yazaki M, Liepnieks JJ, Kincaid JC, Benson MD. Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid. Muscle Nerve 2003; 28: 438-442.
15. Yazaki M, Fushimi T, Tokuda T et al. A patient with severe renal amyloidosis associated with an immunoglobulin gamma-heavy chain fragment. Am J Kidney Dis 2004; 43: e23-28.
16. Yazaki M, Liepnieks JJ, Callaghan J, Connolly CE, Benson MD. Chemical characterization of a lambda I amyloid protein isolated from formalin-fixed and paraffin embedded tissue sections. Amyloid 2004; 11: 50-55.
17. Bergström J, Gustavson Å, Hellman U et al. Amyloid deposits in transthyretin-derived amyloidosis: Cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 2005; 206: 224-232.
18. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: Results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004; 15: 64-71.
19. Saraiva MJM, Birken S, Costa PP, Goodman DS. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 1984; 74: 104-119.
20. Dwulet F, Benson MD. Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. Proc Natl Acad Sci U S A 1984; 81: 694-698.
21. Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 2004; 84: 545-552.
22. Sato T, Ando Y, Susuki S et al. Chromium (III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. FEBS Let 2006; 580: 491-496.
23. Benson MD, Kluve-Beckerman B, Zeldenrust SR et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006; 33: 609-618.